Chloroarenes

Eiger BioPharmaceuticals to Host Conference Call for First Quarter 2021 Financial Results and Business Update on Thursday, May 6, 2021

Retrieved on: 
Thursday, April 29, 2021
Branches of biology, Organic compounds, Chemical compounds, Senescence, Chloroarenes, Orphan drugs, Breakthrough therapy, Lonafarnib, Organobromides, Progeria, Laminopathy, Prenylation

To participate in the live call by phone, dial (844) 743-2495 (U.S.) or (661) 378-9529 (International) and enter conference ID 1090136.

Key Points: 
  • To participate in the live call by phone, dial (844) 743-2495 (U.S.) or (661) 378-9529 (International) and enter conference ID 1090136.
  • Lonafarnib is a first-in-class, oral prenylation inhibitor in a global Phase 3 trial.
  • Peginterferon lambda is a first-in-class, well-tolerated type III interferon entering Phase 3.\nZokinvy for the treatment of Hutchinson-Gilford Progeria Syndrome (HGPS or Progeria) and processing-deficient Progeroid Laminopathies is the Company's first FDA approved product.
  • A Marketing Authorization Application (MAA) is under review by theEuropean Medicines Agency(EMA).\nFor additional information about Eiger and its clinical programs, please visit www.eigerbio.com .\n"

Marinus Pharmaceuticals to Present at Multiple Upcoming Investor Conferences

Retrieved on: 
Wednesday, April 28, 2021
Biotechnology, Pharmaceutical, Health, Psychoactive drugs, Drugs, GABAA receptor positive allosteric modulators, Ketones, Neurochemistry, Sedatives, Chloroarenes, Anticonvulsants, Ganaxolone, Antidepressant, Ketamine, Allosteric regulation

Ganaxolone is a positive allosteric modulator of GABAA receptors that acts on a well-characterized target in the brain known to have anti-seizure, antidepressant and anti-anxiety effects.

Key Points: 
  • Ganaxolone is a positive allosteric modulator of GABAA receptors that acts on a well-characterized target in the brain known to have anti-seizure, antidepressant and anti-anxiety effects.
  • Ganaxolone is being developed in IV and oral dose formulations intended to maximize therapeutic reach to adult and pediatric patient populations in both acute and chronic care settings.
  • The company has initiated a Phase 3 trial in refractory status epilepticus.
  • For more information visit www.marinuspharma.com .\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210428006117/en/\n'

Relmada Therapeutics Announces Poster Presentation at the American Society for Pharmacology and Experimental Therapeutics Annual Meeting at Experimental Biology 2021

Retrieved on: 
Tuesday, April 27, 2021
Major depressive disorder, Antidepressants, Chloroarenes, Selective serotonin reuptake inhibitors

Our clinical program for REL-1017 will evaluate its potential as the first rapid-acting, oral, once-daily antidepressant treatment.

Key Points: 
  • Our clinical program for REL-1017 will evaluate its potential as the first rapid-acting, oral, once-daily antidepressant treatment.
  • In a Phase 2 trial, REL-1017 demonstrated rapid onset and sustained antidepressant effects with statistically significant improvements as compared to placebo.
  • The Phase 2 study also confirmed the favorable safety and tolerability profile of REL-1017 observed in previously completed Phase 1 studies.
  • Relmada undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

Harmony Biosciences To Present WAKIX® (pitolisant) Efficacy and Safety Data at Upcoming 2021 American Psychiatric Association Annual Meeting

Retrieved on: 
Tuesday, April 27, 2021
Branches of biology, Cardiac arrhythmia, Chloroarenes, Circulatory system, Cardiovascular system, Orphan drugs, Cardiac electrophysiology, QT interval, Long QT syndrome, Pitolisant

WAKIX has been commercially available in the U.S. since Q4 2019.

Key Points: 
  • WAKIX has been commercially available in the U.S. since Q4 2019.
  • It was granted orphan drug designation for the treatment of narcolepsy in 2010.
  • WAKIX is extensively metabolized by the liver and there is a significant increase in WAKIX exposure in patients with moderate impairment.\nWAKIX prolongs the QT interval.
  • Avoid use of WAKIX in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval.

China Hydroxychloroquine Markets, 2016-2020 & 2021-2025 - Impact of COVID-19 on the Market

Retrieved on: 
Friday, April 23, 2021
Medical specialties, Medicine, Clinical medicine, Autoimmune diseases, Chloroarenes, Quinolines, Hydroxychloroquine, Arthritis, Rheumatoid arthritis, Lupus, Draft:Chloroquine/Hydroxychloroquine and COVID-19, Triple therapy

In 2020, China\'s sales of hydroxychloroquine were CNY 343 million, a slight increase of 0.71% than 2019.\nHydroxychloroquine is commonly used to prevent and treat malaria.

Key Points: 
  • In 2020, China\'s sales of hydroxychloroquine were CNY 343 million, a slight increase of 0.71% than 2019.\nHydroxychloroquine is commonly used to prevent and treat malaria.
  • Hydroxychloroquine is also used in the treatment of rheumatoid arthritis, lupus erythematosus, and delayed skin lesions purpura.\nThe market demand for hydroxychloroquine in China is relatively large.
  • In March 2020, the Shanghai Municipal Health Commission in China recommended that hydroxychloroquine be used to treat mild to moderate new coronavirus diseases.
  • It is predicted that its sales will gradually return to the original level, that is, it is mainly used for the treatment of malaria and rheumatoid arthritis.\n2 Sales of Hydroxychloroquine in China, 2016-2020\n2.3 Sales of Hydroxychloroquine by Dosage Form in China, 2016-2020\n3 Analysis of Major Hydroxychloroquine Manufacturers in China, 2016-2020\n3.2 Shanghai Zhongxi Pharmaceutical Co.,Ltd.\n4 Prices of Hydroxychloroquine in China, 2020-2021\n5 Prospect of China\'s Hydroxychloroquine Market, 2021-2025\n'

Vincerx Pharma Announces FDA Clearance of IND for Phase 1b Study of VIP152 in Chronic Lymphocytic Leukemia and Richter Syndrome

Retrieved on: 
Tuesday, April 20, 2021
Chemical compounds, Organic compounds, Antineoplastic drugs, Orphan drugs, Breakthrough therapy, Chloroarenes, Sulfonamides, Venetoclax, Tat

\xe2\x80\x9cPreclinical data for VIP152 show highly selective, ATP-independent, inhibition of CDK9 which translates to robust on-target activity across key gene targets.

Key Points: 
  • \xe2\x80\x9cPreclinical data for VIP152 show highly selective, ATP-independent, inhibition of CDK9 which translates to robust on-target activity across key gene targets.
  • Part 1 of the study will enroll CLL patients treated with \xe2\x89\xa52 prior regimens including either a BTKi or venetoclax.
  • The Company expects to initiate the Phase 1b dose-escalation study in 2H 2021.\nThe Phase 1b dose-escalation in CLL and RS builds upon Vincerx\xe2\x80\x99s ongoing first-in-human (FIH) study in patients with advanced cancer.
  • Forward-looking statements speak only as of the date hereof, and Vincerx disclaims any obligation to update any forward-looking statements.\n'

PharmaTher Announces Submission of IND Application with the FDA for Phase 2 Clinical Trial Evaluating Ketamine in the Treatment of Parkinson’s Disease

Retrieved on: 
Tuesday, April 20, 2021
Branches of biology, Nervous system, Drugs, Parkinson's disease, General anesthetics, Chloroarenes, Ketamine, Sedatives, Dyskinesia, Pain, Lou Gehrig

Parkinson\xe2\x80\x99s disease and Lou Gehrig\xe2\x80\x99s disease), mental illness (ie.

Key Points: 
  • Parkinson\xe2\x80\x99s disease and Lou Gehrig\xe2\x80\x99s disease), mental illness (ie.
  • The possible therapeutic effect of low-dose ketamine on LID was noted in a retrospective analysis of PD patients who received ketamine for pain relief.
  • During this analysis, it was observed that the patients experienced an improvement in LID lasting several weeks beyond treatment [Sherman et al, 2016].
  • The primary end-point of the study is the change in the Unified Dyskinesia Rating Scale (\xe2\x80\x9cUDysRS\xe2\x80\x9d) total score from Baseline to Week 8.

Hydroxychloroquine Sees a Drop in Demand and Price, Says Beroe Inc

Retrieved on: 
Thursday, April 22, 2021
Chloroarenes, Quinolines, Hydroxychloroquine, Demand, Pricing, Health care

The demand for hydroxychloroquine was at its peak in the second quarter of 2020, when it was being used in the treatment of COVID-19.

Key Points: 
  • The demand for hydroxychloroquine was at its peak in the second quarter of 2020, when it was being used in the treatment of COVID-19.
  • On average, the API prices had increased by 1015 percent, and in some cases, the prices went up by more than 50 percent.
  • The unpredicted rise in the demand of HCQ drove up the prices from June 2020.
  • With no supply-demand crunch, the prices of raw materials are expected to stabilize in the future.\nThe report from Beroe includes:\n"

Hydroxychloroquine Sees a Drop in Demand and Price, Says Beroe Inc

Retrieved on: 
Thursday, April 22, 2021
Chloroarenes, Quinolines, Hydroxychloroquine, Demand, Pricing, Health care

The demand for hydroxychloroquine was at its peak in the second quarter of 2020, when it was being used in the treatment of COVID-19.

Key Points: 
  • The demand for hydroxychloroquine was at its peak in the second quarter of 2020, when it was being used in the treatment of COVID-19.
  • On average, the API prices had increased by 1015 percent, and in some cases, the prices went up by more than 50 percent.
  • The unpredicted rise in the demand of HCQ drove up the prices from June 2020.
  • With no supply-demand crunch, the prices of raw materials are expected to stabilize in the future.\nThe report from Beroe includes:\n"

China Hydroxychloroquine Market Investigation Report 2021-2025 Featuring Shanghai Zhongxi Pharmaceutical & Sanofi-aventis Ireland - ResearchAndMarkets.com

Retrieved on: 
Monday, April 19, 2021
Manufacturing, Infectious diseases, Health, Pharmaceutical, Chemicals, Plastics, Medical specialties, Medicine, Clinical medicine, Autoimmune diseases, Chloroarenes, Quinolines, Hydroxychloroquine, Sanofi, Rheumatoid arthritis, Lupus, Draft:Chloroquine/Hydroxychloroquine and COVID-19

Hydroxychloroquine is also used in the treatment of rheumatoid arthritis, lupus erythematosus, and delayed skin lesions purpura.\nThe market demand for hydroxychloroquine in China is relatively large.

Key Points: 
  • Hydroxychloroquine is also used in the treatment of rheumatoid arthritis, lupus erythematosus, and delayed skin lesions purpura.\nThe market demand for hydroxychloroquine in China is relatively large.
  • There are two companies approved for manufacturing hydroxychloroquine, namely Shanghai Zhongxi Pharmaceutical Co., Ltd. and Sanofi-aventis Ireland Ltd. Shanghai Zhongxi Pharmaceutical Co., Ltd. has a larger sales market share with lower prices advantage.
  • In March 2020, the Shanghai Municipal Health Commission in China recommended that hydroxychloroquine be used to treat mild to moderate new coronavirus diseases.
  • It is predicted that its sales will gradually return to the original level, that is, it is mainly used for the treatment of malaria and rheumatoid arthritis.\n2 Sales of Hydroxychloroquine in China, 2016-2020\n2.3 Sales of Hydroxychloroquine by Dosage Form in China, 2016-2020\n3 Analysis of Major Hydroxychloroquine Manufacturers in China, 2016-2020\n3.2 Shanghai Zhongxi Pharmaceutical Co.,Ltd.\n4 Prices of Hydroxychloroquine in China, 2020-2021\n5 Prospect of China\'s Hydroxychloroquine Market, 2021-2025\n'